TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15007735

Group type: EXPERIMENTAL
Intervention: Enhanced hygiene practices in DCCs
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control DCCs (no enhanced hygiene practices)
Number of subjects: 288
Study: 11460609

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (containing tetrasodium pyrophosphate, sodium tripolyphosphate, and a copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Positive Control Dentifrice (containing tetrasodium pyrophosphate and a copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 73
Study: 9187973

Group type: EXPERIMENTAL
Intervention: Running Training (RT) at 200% of normal training distance
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cross Training (CT) with running (100% normal training) and cycling (100% normal training)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (normal training at 57.5 +/- 10.9 km.wk-1)
Number of subjects: 11
Study: 7903132

Group type: EXPERIMENTAL
Intervention: Diclofenac retard 100 mg + Roxatidine 150 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diclofenac retard 100 mg + Placebo
Number of subjects: 20
Study: 3981482

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voluntary control over muscle spasming (evidenced by lowered EMG readings)
Number of subjects: 0
Study: 30008985

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: H1 antihistamines (both desloratadine and levocetirizine)
Number of subjects: 79
Study: 27833048

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - 2-day severe energy restriction (1670-2500 kJ/day) with 5 days of habitual eating for 12 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) - moderate diet (5000-6500 kJ/day) for 12 weeks
Number of subjects: 63
Study: 24184313

Group type: EXPERIMENTAL
Intervention: 75mg once-monthly risedronate
Number of subjects: 850

Group type: COMPARATOR
Intervention: 2.5mg once-daily risedronate
Number of subjects: 850
Study: 21450251

Group type: COMPARATOR
Intervention: Internet-based behavioral skills training and knowledge building for NAs
Number of subjects: 86

Group type: COMPARATOR
Intervention: Internet-based behavioral skills training and knowledge building for LHPs
Number of subjects: 86
Study: 20367091

Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Laterally Positioned Flap (LPF)
Number of subjects: 36
Study: 18408387

Group type: COMPARATOR
Intervention: Amodiaquine (AMQ) alone (10 mg AMQ base/kg daily for 3 days)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AMQ) plus chlorpheniramine (CP) (AMQCP) for 7 days (10 mg AMQ base/kg daily for 3 days)
Number of subjects: 103
Study: 16485514

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12453126

Group type: EXPERIMENTAL
Intervention: Immediate loading of four ITI implants with Octa abutments and a U-shaped Dolder gold bar after 2 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed loading of four ITI implants with Octa abutments after 3-4 months.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immediate loading of implants with a U-shaped bar.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immediate loading method.
Number of subjects: 20
Study: 10030287

Group type: COMPARATOR
Intervention: tacrolimus/prednisone
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: tacrolimus/prednisone/mycophenolate mofetil
Number of subjects: 208
Study: 8719169

Group type: EXPERIMENTAL
Intervention: Lead exposure
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (non-exposed workers)
Number of subjects: 54
Study: 2036244

Group type: EXPERIMENTAL
Intervention: Thiethylperazine (6.5 mg p.o every 8 h x 3 days) plus methylprednisolone (250 mg i.v. x 2 doses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Thiethylperazine plus placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Thiethylperazine plus methylprednisolone
Number of subjects: 46
Study: 6790985

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no granulocyte transfusions)
Number of subjects: 102
Study: 31036286

Group type: EXPERIMENTAL
Intervention: Aprepitant (APR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosaprepitant (FosAPR)
Number of subjects: 0
Study: 28861338

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 25465217

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No capsular tension ring (Control group)
Number of subjects: 30
Study: 23160261

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CYP) with corticosteroids and plasmapheresis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral cyclophosphamide (CYP) with plasmapheresis and prednisolone (from MEPEX trial)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CYP)
Number of subjects: 41
Study: 21685706

Group type: EXPERIMENTAL
Intervention: Postprandial exercise (performed 50 min before fat intake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preprandial exercise (performed 20 min after fat intake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study: 19841835

Group type: EXPERIMENTAL
Intervention: Virtual reality‐based system delivered via the Internet for motor tasks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional physical therapy for the upper limb
Number of subjects: 36
Study: 17014748

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Education and Support Group (EAS)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard Medical Care (SMC)
Number of subjects: 153
Study: 15307942

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: No drug (ND)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU)
Number of subjects: 100
Study: 11189686

Group type: EXPERIMENTAL
Intervention: Data management systems developed for the PLCO trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applications for data entry, editing, trial management, reporting, telecommunications, and data sharing
Number of subjects: 0
Study: 9009296

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA and CVD 906-htrA vaccine strains at doses of 5 x 10(7) to 5 x 10(9) CFU
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA and CVD 906-htrA vaccine strains at doses of 5 x 10(8) to 5 x 10(9) CFU
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA and CVD 906-htrA vaccine strains
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA and CVD 906-htrA vaccine strains at higher doses
Number of subjects: 36
Study: 8388286

Group type: EXPERIMENTAL
Intervention: Cimetidine suspension
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo suspension
Number of subjects: 60
Study: 3476523

Group type: EXPERIMENTAL
Intervention: 2800 ppm F as SMFP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1100 ppm F as NaF (positive control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2800 ppm F as NaF
Number of subjects: 0
Study: 31995787

Group type: EXPERIMENTAL
Intervention: Rugby-specific sprint interval training (SITr/s)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Running-only sprint interval training (SITr)
Number of subjects: 31
Study: 28834248

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA; 75 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU; 1200 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Weight-stack training (WS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Flywheel ergometer training (FW)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU)
Number of subjects: 31
Study: 26518190

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg taken 30 min before a meal (pre-Met protocol)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metformin 1000 mg taken with a meal (Met protocol)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metformin 600 mg/kg taken 10 min before a meal (pre-Met)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metformin 600 mg/kg taken with a meal (Met)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Total GLP-1 level at t = 30 min of pre-Met protocol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Total GLP-1 level at t = 0 min of pre-Met
Number of subjects: 23
Study: 25552525

Group type: EXPERIMENTAL
Intervention: Stroke support person-directed intervention
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Self-directed intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 31
Study: 23065707

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant radiotherapy (group 1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Irradiated tumor tissue (group 1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Colorectal cancer patients not undergoing neo-adjuvant radiotherapy (group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-cancer patient group (group 3)
Number of subjects: 3
Study: 20924392

Group type: EXPERIMENTAL
Intervention: Barley β-glucan
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 18250365

Group type: EXPERIMENTAL
Intervention: Dietary nitrate load (beetroot juice 500 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interruption of the enterosalivary conversion of nitrate to nitrite
Number of subjects: 0
Study: 15167995

Group type: EXPERIMENTAL
Intervention: Intrafascial abdominal hysterectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Extrafascial abdominal hysterectomy
Number of subjects: 80
Study: 11826763

Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (FSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urinary follicle-stimulating hormone (FSH)
Number of subjects: 0
Study: 9505770

Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine (0.048% w/v in early labour)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine (0.140% w/v in late labour)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Comparison of MLAC in early vs late labour
Number of subjects: 2
Study: 8113458

Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.1% cream applied twice daily for 24 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (vehicle) applied twice daily for 24 weeks
Number of subjects: 100
Study: 3291837

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol and 0.1% dipivefrin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1% levobunolol and 0.1% dipivefrin
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.5% timolol and 0.1% dipivefrin
Number of subjects: 43
Study: 31931687

Group type: EXPERIMENTAL
Intervention: UCD MCQs (2010-2018)
Number of subjects: 200

Group type: COMPARATOR
Intervention: UCD MCQs (2002-2009)
Number of subjects: 200

Group type: COMPARATOR
Intervention: NBDE MCQs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Quality of MCQs
Number of subjects: 200
Study: 30169607

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 0
Study: 28583466

Group type: EXPERIMENTAL
Intervention: Falls (≥1 falls after stroke)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No falls (control group)
Number of subjects: 250
Study: 25183453

Group type: EXPERIMENTAL
Intervention: Beer (30 g alcohol/d, 660 mL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non‐alcoholic beer (990 mL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gin (30 g alcohol/d, 100 mL)
Number of subjects: 33
Study: 23219367

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 22
Study: 22021535

Group type: EXPERIMENTAL
Intervention: MRI group (3-T MRI before biopsy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-MRI group (no MRI before biopsy)
Number of subjects: 85
Study: 18179676

Group type: EXPERIMENTAL
Intervention: pegaptanib
Number of subjects: 3

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 3
Study: 17201073

Group type: EXPERIMENTAL
Intervention: Submaximal lengthening contractions (10 sets of 60 contractions at 10% maximum isometric strength, 1 min rest between sets)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximal lengthening contractions (10 sets of 3 contractions at 100% maximum isometric strength, 3 min rest between sets)
Number of subjects: 10
Study: 15352639

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 10687326

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 26
Study: 9342580

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg) + Atenolol (100 mg)
Number of subjects: 12
Study: 8211873

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3775691

Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31867657

Group type: EXPERIMENTAL
Intervention: Percentage description
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Concise language description
Number of subjects: 1353
Study: 30010794

Group type: EXPERIMENTAL
Intervention: Soil-transmitted helminth (STH) infections (Ascaris, Trichuris, hookworm)
Number of subjects: 781
Study: 27217455

Group type: EXPERIMENTAL
Intervention: Tamoxifen (Tam)
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Letrozole (Let)
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by Letrozole (Tam-Let)
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Letrozole followed by Tamoxifen (Let-Tam)
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone (Tam)
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Letrozole alone (Let)
Number of subjects: 6144
Study: 24444418

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics approach
Number of subjects: 181
Study: 23078492

Group type: EXPERIMENTAL
Intervention: Education, distribution, and fitting program
Number of subjects: 689
Study: 20166409

Group type: COMPARATOR
Intervention: SRing: sectional matrix and separation ring (Garrison Dental)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CRing: circumferential matrix (1101-c, KerrHawe SA) with separation ring
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CElliot: circumferential matrix and Elliot separator (PFINGST & Co)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CWedge: circumferential matrix with a wedge only
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: COptra: circumferential matrix and OptraContact (Vivadent)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CCerana: circumferential matrix and a Cerana insert (Nordiska Dental)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Walser: Walser matrix O-type (Dr Walser Dental GmbH)
Number of subjects: 105
Study: 19060998

Group type: EXPERIMENTAL
Intervention: Global posture reeducation group (n=15) performing muscle chain stretching
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional stretching group (n=16) performing conventional static muscle stretching
Number of subjects: 33
Study: 15723227

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11908904

Group type: EXPERIMENTAL
Intervention: Oleic acid (OL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stearic acid (STE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low molecular weight saturated fatty acids (LMP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Trans fatty acids + Stearic acid (TFA + STE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TFA/STE
Number of subjects: 50
Study: 10477976

Group type: EXPERIMENTAL
Intervention: Triclosan/NaF dentifrice (0.3% triclosan and 1100 ppm fluoride)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control dentifrice (1100 ppm fluoride)
Number of subjects: 159
Study: 8132906

Group type: EXPERIMENTAL
Intervention: Cues centered at 1 kHz (on-frequency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues centered at 900 Hz (off-frequency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues centered at 700 Hz (off-frequency)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roving the level of stimuli over a 40-dB range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masking waveform frozen within trials
Number of subjects: 0
Study: 2674029

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg/per os/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrazepam (5.0 mg/per os/day)
Number of subjects: 20
Study: 4731336

Group type: EXPERIMENTAL
Intervention: Amitriptyline (10 to 60 mg, usually taken at night)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30388905

Group type: EXPERIMENTAL
Intervention: Taekwondo training (TT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 28506387

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no atorvastatin treatment)
Number of subjects: 32
Study: 25559011

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (DSS)
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Chart-Based Support (CBS)
Number of subjects: 1628
Study: 23220855

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (Group OP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intravenous paracetamol (Group IP)
Number of subjects: 130
Study: 21496253

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (TA) - loading dose 4 g over 1 hour, then infusion of 1 g/hour over 6 hours
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (TA)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 144
Study: 18078985

Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 624
Study: 16423029

Group type: EXPERIMENTAL
Intervention: Delton resin-based sealant
Number of subjects: 153

Group type: COMPARATOR
Intervention: Fuji III glass-ionomer sealant
Number of subjects: 153
Study: 15354382

Group type: EXPERIMENTAL
Intervention: Water rinse after formula consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula consumption without water rinse
Number of subjects: 0
Study: 16144822

Group type: EXPERIMENTAL
Intervention: Preeclamptic women (PE)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Preeclamptic women (PE) and healthy pregnant women (HP) pooled
Number of subjects: 38
Study: 10501749

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg per min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dopexamine (1 microg/kg per min)
Number of subjects: 24
Study: 8723574

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 to 600 IU/kg twice weekly for 3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral iron saccharate supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1885422

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro data
Number of subjects: 0
Study: 6888708

Group type: EXPERIMENTAL
Intervention: Nicotine (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study: 28893208

Group type: EXPERIMENTAL
Intervention: Intravenous patisiran 0.3 mg/kg once every 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27692131

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24170814

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) at an initial dose of 1000 mg iron with subsequent dosing as necessary to target a serum ferritin level of 400-600 µg/L
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) at an initial dose of 200 mg with subsequent dosing as necessary to target serum ferritin 100-200 µg/L
Number of subjects: 626

Group type: COMPARATOR
Intervention: Oral ferrous sulphate 200 mg iron/day
Number of subjects: 626
Study: 21787450

Group type: COMPARATOR
Intervention: Mediterranean diet (MedDiet) without weight loss
Number of subjects: 19

Group type: COMPARATOR
Intervention: Mediterranean diet (MedDiet) with weight loss
Number of subjects: 19

Group type: COMPARATOR
Intervention: North American control diet
Number of subjects: 19
Study: 19488608

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin measurement
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (20 outpatients with IBD)
Number of subjects: 65